Загрузка...
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019)
INTRODUCTION: Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members. An increasing amount of evidence from clinical and preclinical research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer,...
Сохранить в:
| Опубликовано в: : | Expert Opin Ther Pat |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6950832/ https://ncbi.nlm.nih.gov/pubmed/31865813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543776.2019.1708901 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|